Ablynx NV (ABLX.BR) News| Reuters.com
Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.31EUR
11:20am EDT
Change (% chg)

€0.49 (+4.53%)
Prev Close
€10.81
Open
€11.41
Day's High
€11.48
Day's Low
€11.11
Volume
221,166
Avg. Vol
170,537
52-wk High
€16.20
52-wk Low
€10.00

Select another date:

BRIEF-Vectura says Ablynx to exercise a license option on Fox device

* Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Van Herk Investments announce 3.02 pct shareholding in Ablynx

* Van Herk Investments announce 3.02 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Ablynx successfully raises 74.2 mln euros

* Announced on Wednesday that it has raised 74.2 million euros ($83.1 million) through a private placement of new shares via an accelerated book building procedure announced on June 1, 2016

BRIEF-Ablynx to raise capital through private placement of new shares

* To raise gross proceeds of up to approximately 60 million euro ($67.0 million)

BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab

* Ablynx to present a post-hoc analysis of the Phase II TITAN study with caplacizumab in acquired TTP patients at the 21st congress of the European hematology association

Ablynx burns more cash in first-quarter on higher R&D costs

Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.

Ablynx burns more cash in Q1 on higher R&D costs

May 12 Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.

BRIEF-Ablynx Q1 cash position up at 233.7 million euros

* Q1 revenues up 94 pct to 27.4 million euros ($31.3 million)(Q1 2015: 14.1 million euros)

BRIEF-Ablynx meets primary endpoint in anti-RSV nanobody phase I/IIa study

* Reports positive top line results for its inhaled anti-RSV nanobody (ALX-0171) in a phase I/IIa study in infants hospitalized with an RSV infection

BRIEF-Ablynx to receive EUR 8 mln milestone as Boehringer Ingelheim starts Phase I study

* Ablynx to receive an 8 million euros ($9.03 million) milestone as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody Source text for Eikon: Further company coverage: ($1 = 0.8855 euros) (Gdynia Newsroom)

Select another date: